ReACp53 was tested in p53-mutant PCa cell lines, and the results showed that the drug restored the transcriptional effects of p53 and reduced DNA synthesis of p53 mutant cells, thereby being another interesting potential target for further clinical trials [89]. The gene discussed is TP53; the disease is posterior cortical atrophy.